Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

RESTRAIN-SUI

Eli Lilly · Phase 3 · Recruiting · Enrollment 1000

NCT07202884

ArmPopulationDoseWeeksEstimandWeight change
Orforglipron (GZS1)Urinary Incontinence,Stressn/r58n/rn/r
Placebo (GZS1)Urinary Incontinence,Stressn/r58n/rn/r
Orforglipron (GZS2)Urinary Incontinence,Stressn/r58n/rn/r
Placebo (GZS2)Urinary Incontinence,Stressn/r58n/rn/r